ArticleMediators of inflammation2025
Comprehensive Single-Cell Characterization of LDL in the Ovarian Cancer Microenvironment and Its Prognostic Implications.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Single-Cell Characterization of LDL in the Ovarian Cancer Microenvironment and Its Prognostic Implications.Mediators of inflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-density lipoprotein (LDL) is a critical regulator of lipid metabolism and has been implicated in the development and progression of various malignancies. However, its specific roles and mechanisms in the ovarian cancer tumor microenvironment (TME) remain unclear. This study aimed to comprehensively elucidate the distribution, functional pathways, and prognostic value of LDL in ovarian cancer using single-cell transcriptome analysis. Methods: Single-cell transcriptome data from ovarian cancer patients were analyzed. The AUCell algorithm was used to score LDL-related gene expression in different cell subsets, dividing cells into high and low LDL score groups. Functional pathway enrichment (Gene Set Variation Analysis [GSVA]) and cell-cell communication (CellChat) analyses were performed. Differentially expressed genes (DEGs) identified between the two groups were combined with bulk RNA-seq data from eight cohorts to construct the LDL-related ovarian cancer prognostic signature (LDLOCPS) using machine learning. Prognostic performance and immune landscape differences were evaluated between high and low LDLOCPS groups. Results: LDL was predominantly highly expressed in myeloid cells (macrophages and monocytes) and stromal cells (fibroblasts, smooth muscle cells, and endothelial cells) within the ovarian cancer TME. GSVA revealed that the high LDL score group was significantly enriched for pathways including epithelial-mesenchymal transition (EMT), inflammatory response, coagulation, and angiogenesis. CellChat analysis demonstrated enhanced cell-cell communication involving IL6, CSF, and tenascin in the high LDL score group, with SPP1+ macrophages and monocytes showing stronger incoming and outgoing signals. The LDLOCPS model, constructed from bulk transcriptomic data and validated across eight cohorts, effectively stratified patients by risk; the high LDLOCPS group exhibited significantly worse overall survival. Receiver operating characteristic (ROC) and principal component analysis (PCA) analyses confirmed the robust predictive performance of LDLOCPS. Moreover, patients in the high LDLOCPS group showed reduced immune cell infiltration and lower expression of immune-related genes, suggesting an immunosuppressive microenvironment. Conclusion: This study systematically reveals the spatial distribution of LDL within the ovarian cancer microenvironment and uncovers its regulatory roles in tumor progression through multiple signaling pathways. The LDLOCPS model provides a valuable tool for risk stratification and prognosis prediction in ovarian cancer. LDL-mediated microenvironmental and immunosuppressive effects may offer novel insights for developing targeted and immunomodulatory therapies in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.